Oppenheimer on Cytokinetics (CYTK): 'We stay bullish'

Cytokinetics (CYTK) PT Raised to $86 at Truist, 'recent data further support CYTK as an attractive M&A target'

Truist Securities analyst Srikripa Devarakonda raised the price target on Cytokinetics (NASDAQ: CYTK) to $86.00 (from $60.00) while maintaining a Buy rating.

The analyst comments "Following mgmt conference call on Ph3 SEQUOIA-HCM data and speaking with mgmt postconference call, our conviction around best-in-class potential for... More

Cytokinetics (CYTK) PT Raised to $107 at Oppenheimer, 'We Stay Bullish'

Oppenheimer analyst Justin Kim raised the price target on Cytokinetics (NASDAQ: CYTK) to $107.00 (from $54.00) while maintaining a Outperform rating.

The analyst comments "Aficamten appears on course toward a best-in-class trajectory in the treatment of oHCM following Phase 3 SEQUOIA results. With the call offering... More

Mizuho on Cytokinetics (CYTK): 'Investors will now likely shift the debate back to M&A'

Mizuho Securities analyst Salim Syed reiterated a Buy rating and $80.00 price target on Cytokinetics (NASDAQ: CYTK).

The analyst comments "This morning, Cytokinetics announced aficamten's Ph3 SEQUOIA-HCM results in obstructive hypertrophic cardiomyopathy (oHCM) patients. The data read very clean -- numerically better on... More

Truist on Cytokinetics (CYTK): 'We See Best In Class Potential for aficamten'

Truist Securities analyst Srikripa Devarakonda reiterated a Buy rating and $60.00 price target on Cytokinetics (NASDAQ: CYTK)

The analyst comments "SEQUOIA-HCM was in line with our expectations. The trial hit as pVO2 improvements, the primary endpoint, were stat sig (p=0.000002) vs. placebo and numerically better vs. Camzyos. Given these data, we see best-in-class... More

B.Riley on Cytokinetics (CYTK): 'Remain Buyers'

B.Riley analyst Mayank Mamtani reiterated a Buy rating and $66.00 price target on Cytokinetics (NASDAQ: CYTK).

The analyst comments "On 12/27 BMO, Cytokinetics (CYTKBuy, $66 PT) reported strong top-line pivotal Ph. III SEQUOIA-HCM study (n=282) results of aficamten (afi) in obstructive hypertrophic cardiomyopathy (oHCM); notably... More

Cytokinetics (CYTK) Announces Positive Results From SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced positive topline results from SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM), the pivotal Phase 3... More

Cytokinetics (CYTK) to Host Investor Call on December 27 to Discuss the Topline Results from SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with HCM

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of its senior management will host an investor call at 8:30 AM Eastern Time on Wednesday, December 27, 2023 to discuss the topline results from SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM), the pivotal Phase 3 clinical trial of aficamten, an investigational medicine, in patients with symptomatic obstructive hypertrophic cardiomyopathy... More